← Issue №18/ week of Nov 1, 2026/Esophagus/Reflux

Meta-Analysis: Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastroprotection in Patients Receiving Antiplatelet Therapy.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Esophagus/Reflux meta analysis · n=34,123 · Oct 28, 2026 · Aliment Pharm Ther · IF 6.7

Meta-Analysis: Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastroprotection in Patients Receiving Antiplatelet Therapy.

New evidencemeta-analysisproton pump inhibitors
Clinical takeawayNo clinical action yet: findings on MACE and revascularisation are from observational studies and require confirmation in randomised trials.
What it foundP-CABs showed no statistically significant difference from PPIs in gastrointestinal bleeding (RR 0.89, 95% CI 0.67-1.18), but observational studies suggested lower MACE (RR 0.80, 0.65-0.98) and revascularisation (RR 0.77, 0.59-0.99) rates with P-CABs.
ContextConfirms PPIs remain standard for gastroprotection during antiplatelet therapy; observational data suggest potential cardiovascular benefits with P-CABs, but evidence is insufficient to change practice.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mansk PG … Mahajan K · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues